Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Am J Surg Pathol. 2022 Nov 3;47(2):270–277. doi: 10.1097/PAS.0000000000001997

Table 2.

Immunohistochemical (IHC) and Molecular Findings

Case IHC (+) IHC (−) TRAF7 (NM_032271) mutation TRAF7 mutation variant allele frequency Copy number alterations Sarcoma methylation classifier Calibration score
1 SMA Desmin, S100, melan-A, beta-catenin, MUC4, CD34, keratins, STAT6, beta catenin c.1192C>T (p.P398S), c.1730A>G (p.Y577S) 6.1%, 8.0% CDKN2A/B loss Undifferentiated sarcoma (USARC) 0.79771
2 CD34, SMA (focal), GLUT1 SOX10, S100, EMA, pan-NTRK, ALK-1, MUC4, STAT6, desmin, beta-catenin and ER. c.1606G>A (p.G536S) 21.5% 1p, 12q12–13, 16q arm level loss Undifferentiated sarcoma (USARC) 0.98635
3 WT1, CD34, PR, scattered MDM2 CK, histiocytic CD1a CD163 CD68, calretinin, melanocytic markers, PAX8, SMA, desmin, ALK D5F3, SMARCA4 retained, SMARCB1 retained, CDK4 c.1896C>G (p.N632K) 14.2% 12q arm level gain, 20q13 gain, 16q12 gain Undifferentiated sarcoma (USARC) 0.33081